Tineke Kraaij
Leiden University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tineke Kraaij.
Autoimmunity Reviews | 2016
Tineke Kraaij; Fredrik C. Tengström; Sylvia W.A. Kamerling; Charles D. Pusey; H. Ulrich Scherer; René E. M. Toes; Ton J. Rabelink; Cees van Kooten; Y.K. Onno Teng
A newly-described first-line immune defence mechanism of neutrophils is the release of neutrophil extracellular traps (NETs). Immune complexes (ICxs) induce low level NET release. As such, the in vitro quantification of NETs is challenging with current methodologies. In order to investigate the role of NET release in ICx-mediated autoimmune diseases, we developed a highly sensitive and automated method for quantification of NETs. After labelling human neutrophils with PKH26 and extracellular DNA with Sytox green, cells are fixed and automatically imaged with 3-dimensional confocal laser scanning microscopy (3D-CLSM). NET release is then quantified with digital image analysis whereby the NET amount (Sytox green area) is corrected for the number of imaged neutrophils (PKH26 area). A high sensitivity of the assay is achieved by a) significantly augmenting the area of the well imaged (11%) as compared to conventional assays (0.5%) and b) using a 3D imaging technique for optimal capture of NETs, which are topologically superimposed on neutrophils. In this assay, we confirmed low levels of NET release upon human ICx stimulation which were positive for citrullinated histones and neutrophil elastase. In contrast to PMA-induced NET release, ICx-induced NET release was unchanged when co-incubated with diphenyleneiodonium (DPI). We were able to quantify NET release upon stimulation with serum from RA and SLE patients, which was not observed with normal human serum. To our knowledge, this is the first semi-automated assay capable of sensitive detection and quantification of NET release at a low threshold by using 3D CLSM. The assay is applicable in a high-throughput manner and allows the in vitro analysis of NET release in ICx-mediated autoimmune diseases.
Lupus science & medicine | 2016
Tineke Kraaij; Obbo W. Bredewold; Stella Trompet; Tom W J Huizinga; Ton J. Rabelink; Anton J. M. de Craen; Y.K. Onno Teng
Current guidelines do not mention tacrolimus (TAC) as a treatment option and no consensus has been reported on the role of TAC in lupus nephritis (LN). The present study aimed to guide clinical judgement on the use of TAC in patients with LN. A meta-analysis was performed for clinical studies investigating TAC regimens in LN on the basis of treatment target (induction or maintenance), concomitant immunosuppression and quality of the data. 23 clinical studies performed in patients with LN were identified: 6 case series, 9 cohort studies, 2 case-control studies and 6 randomised controlled trials (RCTs). Of the 6 RCTs, 5 RCTs investigated TAC regimens as induction treatment and 1 RCT as maintenance treatment. Five RCTs investigated TAC in combination with steroids and 2 TAC with mycophenolate plus steroids. All RCTs were performed in patients of Asian ethnicity. In a meta-analysis, TAC regimens achieved a significantly higher total response (relative risk (RR) 1.23, 95% CI 1.12 to 1.34, p<0.05) and significantly higher complete response (RR 1.48, 95% CI 1.23 to 1.77, p<0.05). The positive outcome was predominantly defined by the largest RCT investigating TAC with mycophenolate plus steroids. Regarding safety, the occurrence of leucopoenia was significantly lower, while the occurrence of increased creatine was higher. Clinical studies on TAC regimens for LN are limited to patients of Asian ethnicity and hampered by significant heterogeneity. The positive results on clinical efficacy of TAC as induction treatment in LN cannot be extrapolated beyond Asian patients with LN. Therefore, further confirmation in multiethnic, randomised trials is mandatory. Until then, TAC can be considered in selected patients with LN.
Rheumatology | 2014
Tineke Kraaij; Tom W J Huizinga; Ton J. Rabelink; Y.K. Onno Teng
Journal of Autoimmunity | 2018
Tineke Kraaij; Sylvia W.A. Kamerling; Esther de Rooij; Paul L. A. van Daele; Obbo W. Bredewold; Ja Bakker; Ingeborg M. Bajema; Hu Scherer; Rene Toes; Tom J.W. Huizinga; Ton J. Rabelink; Cees van Kooten; Y.K. Onno Teng
Kidney International | 2018
Tineke Kraaij; Sylvia W.A. Kamerling; Laura S. van Dam; Jaap A. Bakker; Ingeborg M. Bajema; Theresa H. Page; Francesca Brunini; Charles D. Pusey; René E. M. Toes; Hans Ulrich Scherer; Ton J. Rabelink; Cees van Kooten; Y.K. Onno Teng
Kidney International | 2018
Emilie C. Rijnink; Y.K. Onno Teng; Tineke Kraaij; Olaf M. Dekkers; Jan A. Bruijn; Ingeborg M. Bajema
Archive | 2017
Yoe Kie Onno Teng; Tineke Kraaij; Ton J. Rabelink; Cees van Kooten
Nephrology Dialysis Transplantation | 2017
Tineke Kraaij; Sylvia W. A. Kamerling; Jaap A. Bakker; Tom W J Huizinga; Ton J. Rabelink; Cees van Kooten; Y.K. Onno Teng
Nephrology Dialysis Transplantation | 2017
Tineke Kraaij; Sylvia W. A. Kamerling; Esther de Rooij; Paul L. A. van Daele; Ingeborg M. Bajema; Obbo W. Bredewold; Tom W J Huizinga; Ton J. Rabelink; Cees van Kooten; Y.K. Onno Teng
Kidney International Reports | 2016
Tineke Kraaij; Fredrik C. Tengström; Sylvia W.A. Kamerling; Charles D. Pusey; U. Scherer; René E. M. Toes; Ton J. Rabelink; C. van Kooten; O. Teng